Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

This Tech Giant Is Buying Back Stock Hand Over Fist. Insiders Are Buying, Too. Should You Follow?

View original at nasdaq.com
“Last year, Salesforce generated $14.4 billion of free cash flow, and it expects to grow that figure by 10% in fiscal 2027.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce expects to grow free cash flow by 10% in fiscal 2027

    60% confidence

  • Salesforce was not included in the 10 best stocks for investors to buy now

    60% confidence

  • It may take several quarterly earnings reports or updates to convince skeptics that the AI fears are overblown

    60% confidence

  • If signs emerge that Salesforce's platform will be one of the AI survivors or beneficiaries, it could be one of the best buys in the market

    60% confidence

  • Salesforce will be able to harness AI to its advantage rather than be disrupted by it

    60% confidence

  • AI fears over software disruption may be overblown, though confirmation will take years

    60% confidence

  • If Salesforce's internal data and sales professionals can help customers use tokens more effectively in a proprietary way, that could be a recipe for generating value

    60% confidence

Data points we hold from this source

Salesforce · price to fcf9.5 ratio
Salesforce · net debt30 USD
Salesforce · shares outstanding810 millions
Salesforce · shares retired103 millions
Salesforce · share count reduction11.1 percent
Salesforce · shares outstanding923 millions
Salesforce · net debt5 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
This Tech Giant Is Buying Back Stock Hand Over Fist. Insiders Are Buying, Too. Should You Follow? — Source | Via News | Finance Via News